Neutrogena Launches New-Gen BEMT Sunscreens After FDA Approval

Event Details and Background

The US Food and Drug Administration (FDA) added bemotrizinol (BEMT) to the list of permitted sunscreen active ingredients this summer. This is the first new ingredient approved for use in over-the-counter sunscreens in the US since 1999, ending a 25-year hiatus. While BEMT has been used in Europe and Asia for several years, this approval marks a significant update to US sunscreen regulations. Neutrogena is among the first companies to bring sunscreens with the newly approved ingredient to the US market, signaling a new era for sun protection in the country.

Key Data and Practices

Neutrogena launched two new BEMT-based formulations: Ultra Sheer Daily Face Sunscreen SPF 70 and Clear Face Sunscreen SPF 60. The former is ultra-lightweight, claimed to be 50% lighter than leading sunscreens, while the latter is formulated for acne-prone skin. BEMT protects against both UVA and UVB rays. Compared with other US-approved UV filters, BEMT allows for more elegant formulations, making sunscreens more comfortable, wearable, and easier to incorporate into daily routines.

Industry Context

This approval ends a 25-year stagnation in US sunscreen active ingredients, introducing new technical possibilities for the industry. The addition of BEMT not only enriches the sunscreen chemistry but also addresses the pain point of consumer reluctance due to heavy texture by improving skin feel. Although the material does not provide market share or sales figures, Neutrogena established an early advantage in commercializing the new ingredient as one of the first launchers.

Implications for B2B and Brands

For B2B procurement, BEMT's approval implies a need to reassess compliant inventory and raw material demand in the supply chain. Brand owners should focus on the stability data and formulation compatibility of the new ingredient, especially when developing high-protection SPF 50+ products under the "lightweight" trend. From a compliance perspective, while BEMT is already used in Europe and Asia, specific claim restrictions under the latest North American regulatory framework require strict review.